Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast

British Journal of Surgery

Volumn 100, Issue 13, 2013, Pages 1756-1763

  Lee, S K ^a   Yang, J H ^b   Woo, S Y ^c   Lee, J E ^a   Nam, S J ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; NOMOGRAM; PATHOLOGY; PREOPERATIVE CARE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NOMOGRAMS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; YOUNG ADULT;

EID: 84887829390     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9337     Document Type: Article

References (35)

1. Miyake T, Shimazu K, Ohashi H, Taguchi T, Ueda S, Nakayama T, et al,. Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ. Am J Surg 2011; 202: 59-65.
2. Han JS, Molberg KH, Sarode V,. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases. Breast J 2011; 17: 223-229.
3. Houssami N, Ambrogetti D, Marinovich ML, Bianchi S, Macaskill P, Vezzosi V, et al,. Accuracy of a preoperative model for predicting invasive breast cancer in women with ductal carcinoma-in-situ on vacuum-assisted core needle biopsy. Ann Surg Oncol 2011; 18: 1364-1371.
4. Kurniawan ED, Rose A, Mou A, Buchanan M, Collins JP, Wong MH, et al,. Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg 2010; 145: 1098-1104.
5. Brem RF, Schoonjans JM, Goodman SN, Nolten A, Askin FB, Gatewood OM,. Nonpalpable breast cancer: percutaneous diagnosis with 11- and 8-gauge stereotactic vacuum-assisted biopsy devices. Radiology 2001; 219: 793-796.
6. Lambert K, Patani N, Mokbel K,. Ductal carcinoma in situ: recent advances and future prospects. Int J Surg Oncol 2012; 2012: 347385.
7. Moran CJ, Kell MR, Flanagan FL, Kennedy M, Gorey TF, Kerin MJ,. Role of sentinel lymph node biopsy in high-risk ductal carcinoma in situ patients. Am J Surg 2007; 194: 172-175.
8. Huo L, Sneige N, Hunt KK, Albarracin CT, Lopez A, Resetkova E,. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 2006; 107: 1760-1768.
9. Meijnen P, Oldenburg HS, Loo CE, Nieweg OE, Peterse JL, Rutgers EJ,. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg 2007; 94: 952-956.
10. O'Flynn EA, Morel JC, Gonzalez J, Dutt N, Evans D, Wasan R, et al,. Prediction of the presence of invasive disease from the measurement of extent of malignant microcalcification on mammography and ductal carcinoma in situ grade at core biopsy. Clin Radiol 2009; 64: 178-183.
11. Wilkie C, White L, Dupont E, Cantor A, Cox CE,. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg 2005; 190: 563-566.
12. Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, et al,. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005; 200: 516-526.
13. Kim J, Han W, Lee JW, You JM, Shin HC, Ahn SK, et al,. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision. Breast 2012; 21: 641-645.
14. Go EM, Chan SK, Vong JS, Lui PC, Chan AW, Ma TK, et al,. Predictors of invasion in needle core biopsies of the breast with ductal carcinoma in situ. Mod Pathol 2010; 23: 737-742.
15. Lee JW, Han W, Ko E, Cho J, Kim EK, Jung SY, et al,. Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. J Surg Oncol 2008; 98: 15-20.
16. Doyle B, Al-Mudhaffer M, Kennedy MM, O'Doherty A, Flanagan F, McDermott EW, et al,. Sentinel lymph node biopsy in patients with a needle core biopsy diagnosis of ductal carcinoma in situ: is it justified? J Clin Pathol 2009; 62: 534-538.
17. Jackman RJ, Burbank F, Parker SH, Evans WP III, Lechner MC, Richardson TR, et al,. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology 2001; 218: 497-502.
18. Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, et al,. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg 2008; 247: 315-319.
19. Allred DC, Harvey JM, Berardo M, Clark GM,. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
20. College of American Pathologists. Protocol for the Examination of Specimens from Patients with Ductal Carcinoma In Situ (DCIS) of the Breast; 2009. http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/2009/ BreastDCIS-09protocol.pdf [accessed 6 September 2013].
21. Eastham JA, Kattan MW, Scardino PT,. Nomograms as predictive models. Semin Urol Oncol 2002; 20: 108-115.
22. Ballehaninna UK, Chamberlain RS,. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability. J Clin Oncol 2011; 29: e97-e98.
23. Mazouni C, Delaloge S, Rimareix F, Garbay JR,. Nomogram for risk of relapse after breast-conserving surgery in ductal carcinoma in situ. J Clin Oncol 2011; 29: e44.
24. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, et al,. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol 2012; 30: 600-607.
25. Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, et al,. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 2010; 28: 3762-3769.
26. Sakr R, Bezu C, Raoust I, Antoine M, Ettore F, Darcourt J, et al,. The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes. Int J Clin Pract 2008; 62: 1730-1735.
27. Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al,. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011; 260: 119-128.
28. Hung WK, Ying M, Chan M, Mak KL, Chan LK,. The impact of sentinel lymph node biopsy in patients with a core biopsy diagnosis of ductal carcinoma in situ. Breast Cancer 2010; 17: 276-280.
29. Shah DR, Canter RJ, Khatri VP, Bold RJ, Martinez SR,. Utilization of lymph node assessment in patients with ductal carcinoma in situ treated with lumpectomy. J Surg Res 2012; 177: e21-e26.
30. Wang SY, Shamliyan T, Virnig BA, Kane R,. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 2011; 127: 1-14.
31. Veronesi P, Intra M, Vento AR, Naninato P, Caldarella P, Paganelli G, et al,. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast 2005; 14: 520-522.
32. Silverstein MJ, Skinner KA, Lomis TJ,. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001; 25: 767-772.
33. Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, et al,. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 2008; 196: 81-87.
34. Liao N, Zhang GC, Liu YH, Li XR, Yao M, Xu FP, et al,. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathol Res Pract 2011; 207: 1-7.
35. Renshaw AA,. Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ. Arch Pathol Lab Med 2002; 126: 39-41.